Vasopressin-receptor antagonists.
Despite a crucial role in body fluid homeostasis, elevated vasopressin levels can also be pathological in conditions such as congestive heart failure, liver cirrhosis and the syndrome of inappropriate antidiuretic hormone secretion. The result of elevated vasopressin is renal water retention and hyponatremia, a low serum sodium concentration. Hyponatremia is associated with excess morbidity and mortality. Nonpeptide vasopressin-receptor antagonists represent a new drug class of small molecules that competitively inhibit one or more of the vasopressin receptors. There are three vasopressin receptors in humans, including V1a, V1b and V2. Selective V2- and combined V1a/V2-receptor antagonists have been developed for the treatment of hyponatremia resulting from congestive heart failure, liver cirrhosis and the syndrome of inappropriate antidiuretic hormone secretion. Two nonpeptide vasopressin-receptor antagonists, conivaptan and tolvaptan, have recently been approved by American and European drug authorities for clinical use. This article aims to provide a succinct and clinical update on nonpeptide vasopressin-receptor antagonists, including their mechanism of action, performance in randomized clinical trials and current clinical status.
Hoorn
Ewout J
EJ
Department of Internal Medicine, Erasmus Medical Center, 3000 CA Rotterdam, The Netherlands. ejhoorn@gmail.com
Zietse
Robert
R
D065092:Antidiuretic Hormone Receptor Antagonists; D002986:Clinical Trials as Topic; D006801:Humans; D007010:Hyponatremia / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D014667:Vasopressins / Q000502:physiology
D065092:Antidiuretic Hormone Receptor Antagonists; D014667:Vasopressins